Convalescent plasma not effective for treating COVID-19: study
FirstWord Pharma – Gain Access to the Information You Need Track the Companies, Products, and Regulatory Areas of Most Interest to You
Related Articles
U.S. FDA declines to approve Eli Lilly’s drug to treat eczema
The U.S. Food and Drug Administration (FDA) has declined to approve Eli Lilly’s drug to treat a type of skin disease due to certain findings…
Protecting children from poor air quality
3 in 4 parents are concerned about the impact of air quality problems on their child’s health. 2 in 3 parents report poor or unhealthy…
FDA Reviewers Say OTC Decongestant Doesn’t Work
But they acknowledge that taking the only shelf-accessible product off the market raises issues
Nestlé offloads peanut allergy therapy Palforzia to Stallergenes Greer
Nestlé announced Monday the divestment of its peanut allergy treatment business Palforzia (peanut allergen powder-dnfp) to Stallergenes Greer for an undisclosed sum. Nestlé kicked off…
AstraZeneca Halts Phase II Asthma Trial Due to Safety Findings in Toxicology Study | BioSpace
Pieris Pharmaceuticals announced partner AstraZeneca’s decision to discontinue clinical studies of elarekibep, an inhaled IL-4 receptor alpha inhibitor, based on a non-clinical toxicology study.
‘Stunning’ change to United’s colonoscopy coverage roils physicians and patients
For patients who have undiagnosed cancer, a months-long delay due to new prior authorization requirements for colonoscopies could be disastrous.
Dupilumab not linked to short-term cancer development in patients with atopic dermatitis
Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published…
FDA approves leniolisib for activated phosphoinositide 3-kinase delta syndrome
The FDA approved leniolisib as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients 12 years of age and older.